Enzolytics (Enzolytics) Current Deferred Revenue : $0.00 Mil (As of Jun. 2011)

View and export this data going back to 2008. Start your Free Trial

What is Enzolytics Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Enzolytics's current deferred revenue for the quarter that ended in Jun. 2011 was $0.00 Mil.

Enzolytics Current Deferred Revenue Historical Data

The historical data trend for Enzolytics's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzolytics Current Deferred Revenue Chart

Enzolytics Annual Data

Trend

Dec07

Jul08

Dec09

Dec10

Current Deferred Revenue

Enzolytics Quarterly Data
	Sep07	Dec07	Apr08	Jul08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11
Current Deferred Revenue	Get a 7-Day Free Trial										-	-	-	-	-

Enzolytics Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Enzolytics's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Enzolytics (Enzolytics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enzolytics Inc (OTCPK:ENZC) » Definitions » Current Deferred Revenue

Traded in Other Exchanges

N/A

Address

1101 Raintree Circle, Suite 130, Allen, TX, USA, 75013

Website

https://www.enzolytics.com

Enzolytics Inc is a biotechnology company, whose products consist of multiple distinct drug development proprietary technologies: Immunotherapy, immune modulators, fully human monoclonal antibodies, and an artificial intelligence (AI) platform for health care developments. It has clinically tested anti-HIV therapeutics. Additionally, the Company has created a proprietary cell line that produces fully human monoclonal antibodies that target and neutralizes the HIV virus.